Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Feb 09, 2023 8:21pm
111 Views
Post# 35278566

RE:RE:RE:Earnings

RE:RE:RE:EarningsI agree. Expectations are so low right now it might be hard to drive them lower. Two things stand out to me for THTX to address. First, they need to highlight that 1Q sales are on track with guidance, especially since the first quarter is almost over already. Second, they need to layout a feasible, believable and rapid plan to attain balance sheet stability via positive internal cash flow. If positive cash flow is insufficient to achieve the objective, then we need to know what the plan to address that is. 

I would imagine it is possible any delay in getting the fourth quarter financials out faster could be related to discussions with their auditors regarding what write-offs may be required. And they may need to hear from the FDA on TH-1902 first to be able to determine if some of the the goodwill from the Katana acquisition is now viewed as an impaired asset. Or there could be other audit related issues that are more mundane but still delay things. 


<< Previous
Bullboard Posts
Next >>